Fortress Biotech: 3 Key Takeaways for Long-Term Investors

Fortress Biotech (FBIO) delivered strong third-quarter results on its November 12, 2026 earnings call, showing promising growth for long-term investors. Key takeaways include:

1. **Clinical Success**: Emrosi, Fortress Biotech's prescription rosacea treatment, showcased superior efficacy with 30% of patients achieving clear skin compared to only 12.8% for competitor Oracea. This higher symptom clearance translates to greater prescription refills, as patients who reach full clearance remain symptom-free longer. This clinical superiority bolsters Emrosi's best-in-class profile.

2. **Commercial Expansion**: Emrosi reached 40% coverage of the target market, meaning insurance plans reimburse prescriptions with minimal patient step-edits. Currently, 40% of commercial lives have high-quality access to Emrosi. Building on this progress, a major national health plan added Emrosi to its formulary in early August, and an additional larger national plan is expected to follow soon. These commercial advancements position Emrosi favorably for higher net prices per prescription.

3. **Financial Momentum**: The company achieved positive non-GAAP adjusted EBITDA due to lower manufacturing costs for its main drug. This financial milestone, coupled with growing prescription volume across key sales territories, indicates structural advantages for long-term growth. Management is closely monitoring formulary pull-through and prescriber adoption to secure market leadership, viewing Emrosi as a potential oral standard of care for rosacea treatment.